NCT00006004已完成2 期
A Randomized Phase II Trial of Paclitaxel-Carboplatin or Gemicitabine-Cisplatin in ECOG Performance Status 2 Non-Small Cell Lung Cancer Patients
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 16
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective for treating non-small cell lung cancer.
PURPOSE: Randomized phase II trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have non-small cell lung cancer.
详细描述
OBJECTIVES:
- Compare overall survival, response rate, and time to progression of patients with non-small cell lung cancer treated with paclitaxel and carboplatin versus gemcitabine and cisplatin.
- Compare the toxicities of each of these 2 regimens in this patient population.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to weight loss in the past 6 months (less than 5% vs at least 5%) and disease stage (stage IIIB with pleural or pericardial effusion or pleural implants vs stage IV/recurrent). Patients are randomized to one of two treatment arms.
- Arm I: Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 15-30 minutes on day 1.
- Arm II: Patients receive gemcitabine IV over 30 minutes on days 1 and 8 followed by cisplatin IV over 1 hour on day 1 only.
Treatment continues in both arms every 21 days for up to 6 courses in the absence of unacceptable toxicity or disease progression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically confirmed non-small cell lung carcinoma of any of the following subtypes:
- •Squamous cell
- •Adenocarcinoma
- •Large cell anaplastic
- •Bronchioalveolar
- •Non-small cell carcinoma not otherwise specified
- •No small cell anaplastic elements allowed
- •Must have:
- •Recurrent disease after prior radiotherapy or surgery OR
- •Stage IV disease with distant metastases OR
- •Stage IIIB disease presenting with pleural or pericardial effusion on CT or chest x-ray or pleural implants documented pathologically or on CT or chest x-ray
- •Bidimensionally measurable or evaluable disease
- •Brain metastases allowed provided clinically stable after treatment with surgery and/or radiotherapy
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status:
- •Life expectancy:
- •Not specified
- •Hematopoietic:
- •Absolute neutrophil count at least 1,500/mm3
- •Platelet count at least 100,000/mm3
- •Bilirubin no greater than 1.5 mg/dL
- •SGOT no greater than 5 times upper limit of normal
- •Creatinine no greater than 1.5 mg/dL OR
- •Creatinine clearance at least 60 mL/min
- •Cardiovascular:
- •No uncontrolled high blood pressure, unstable angina, or congestive heart failure
- •No myocardial infarction within the past 6 months
- •No serious ventricular arrhythmias requiring medication
- •Not pregnant or nursing
- •Fertile patients must use effective contraception
- •No other active malignancies requiring ongoing treatment
- •No uncontrolled serious active infections
- •No suspected hypersensitivity to agents that utilize Cremophor
- •No evidence of neuropathy grade 2 or greater by history or physical examination
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy:
- •Not specified
- •Chemotherapy:
- •No prior chemotherapy for non-small cell lung cancer
- •Endocrine therapy:
- •Not specified
- •Radiotherapy:
- •See Disease Characteristics
- •No prior radiotherapy to only site of measurable or evaluable disease unless subsequent progression documented by physical exam, radiograph, or pathology
- •Recovered from prior radiotherapy
- •No concurrent radiotherapy except for whole brain radiation for developing brain metastases
- •See Disease Characteristics
排除标准
- 未提供
研究者
研究点 (16)
Loading locations...
相似试验
已完成
2 期
Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast CancerBreast CancerNCT00003612Alliance for Clinical Trials in Oncology92
已完成
2 期
Combination Chemotherapy and Radiation Therapy Followed By Surgery in Treating Patients With Stage IIB or Stage IIIA Non-Small Cell Lung CancerLung CancerNCT00006469Medstar Health Research Institute30
已完成
2 期
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.Carcinoma of Unknown PrimaryLung CancerNCT00003943Fox Chase Cancer Center3
已完成
2 期
Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone TherapyProstate CancerNCT00049257Jonsson Comprehensive Cancer Center58
已完成
2 期
Carboplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal CancerHead and Neck CancerNCT00003206Eastern Cooperative Oncology Group